All In Biotech

Drug Trial Radar · NCT03959085

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy

Last checked: Nov 19, 2026Latest source record: Aug 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 5,951 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

5,951

Planned (sponsor's estimate)

Start

Oct 31, 2019

Primary completion

Mar 31, 2032

Study completion Mar 31, 2032

Sponsor

Lead sponsor
Children's Oncology GroupResearch network
Sponsor type
Research network
Collaborators
National Cancer Institute (NCI)
First posted
May 22, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 365 days, up to 25 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy and immunotherapy (chemo-immunotherapy) for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. Inotuzumab ozogamicin is a monoclonal antibody, which is a type of protein that can bind to certain targets on the surface of cells. Inotuzumab ozogamicin is a monoclonal antibody that is linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells by binding to the CD22 protein on the surface of the cancer cell and delivering calicheamicin inside the cells to kill them. Other drugs used in the chemotherapy regimen, such as cyclophosphamide, cytarabine, dexamethasone, doxorubicin, daunorubicin, methotrexate, leucovorin, mercaptopurine, prednisone, thioguanine, vincristine, and pegaspargase or calaspargase pegol work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Blinatumomab is a specialized type of monoclonal antibody known as a bispecific T-cell engager (BiTE). It works by simultaneously binding to CD19 on cancer cells and CD3 on normal immune cells, bringing them together to destroy leukemia cells. Blinatumomab is a standard part of chemo-immunotherapy treatment for B-ALL. This trial also studies the outcomes of patients with mixed phenotype acute leukemia (MPAL), and B-lymphoblastic lymphoma (B-LLy) when treated with ALL therapy without inotuzumab ozogamicin or blinatumomab. The overall goal of this study is to understand if adding inotuzumab ozogamicin to standard of care chemo-immunotherapy maintains or improves outcomes in High Risk B-cell Acute Lymphoblastic Leukemia (HR B-ALL). The first part of the study includes the first phase of therapy: Induction. This part will collect information on the leukemia, as well as the effects of the initial treatment, to classify patients into post-induction treatment groups. On the second part of this study, patients with HR B-ALL will receive the remainder of the chemotherapy cycles (consolidation, blinatumomab block 1, interim maintenance 1, blinatumomab block 2, delayed intensification, interim maintenance 2, maintenance), with some patients randomized to receive inotuzumab. The patients that receive inotuzumab will not receive part of consolidation or part of delayed intensification. Other aims of this study include evaluating 1) side effects of treatment using patient-reported outcomes and health-related quality of life, 2) the best ways to help patients adhere to oral chemotherapy regimens, 3) the relationship between levels of inotuzumab ozogamicin in the blood and side effects, 4) the impact of chemo-immunotherapy on the immune system and risk of infection, and 5) the impact of social determinants of health on outcomes. Finally, this study will be the first to track the outcomes of subjects with disseminated B-cell Lymphoblastic Leukemia (B-LLy) or Mixed Phenotype Acute Leukemia (MPAL) when treated with B-ALL chemotherapy.

Conditions

  • B Acute Lymphoblastic Leukemia
  • B Lymphoblastic Lymphoma
  • Central Nervous System Leukemia
  • Mixed Phenotype Acute Leukemia
  • Testicular Leukemia

Interventions

  • Biospecimen CollectionProcedure

    Undergo blood sample collection

  • BlinatumomabBiological

    Given IV

  • Bone Marrow AspirationProcedure

    Undergo bone marrow aspiration

  • Bone Marrow BiopsyProcedure

    Undergo bone marrow biopsy

  • Bone ScanProcedure

    Undergo bone scan

  • Calaspargase PegolDrug

    Given IV

  • Computed TomographyProcedure

    Undergo CT

  • CyclophosphamideDrug

    Given IV

  • CytarabineDrug

    Given IV, IT, or SC

  • Daunorubicin HydrochlorideDrug

    Given IV

  • DexamethasoneDrug

    Given PO or IV

  • Doxorubicin HydrochlorideDrug

    Given IV

  • Inotuzumab OzogamicinBiological

    Given IV

  • Leucovorin CalciumDrug

    Given PO or IV

  • Magnetic Resonance ImagingProcedure

    Undergo MRI

  • MercaptopurineDrug

    Given PO

  • MethotrexateDrug

    Given IT or IV

  • PegaspargaseDrug

    Given IV or IM

  • Positron Emission TomographyProcedure

    Undergo PET

  • PrednisoloneDrug

    Given PO or IV

  • PrednisoneDrug

    Given PO or IV

  • Questionnaire AdministrationOther

    Ancillary studies

  • Radiation TherapyRadiation

    Undergo testicular radiation therapy

  • Radiation TherapyRadiation

    Undergo cranial radiation therapy

  • ThioguanineDrug

    Given PO

  • Vincristine SulfateDrug

    Given IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Post-induction 5-year event-free survival (EFS)Time frame: From study entry to first event (induction failure, induction death, end of induction [EOI] minimal residual disease [MRD] ≥ 5%,EO consolidation [C] MRD ≥ 0.01%, relapse, second malignancy, remission death) or date of last contact, assessed up to 5 years

Locations

231 sites in 5 countries. Site status is shown where the registry gives one.

  • Children's Hospital of Alabama

    Birmingham, Alabama · Recruiting

  • USA Health Strada Patient Care Center

    Mobile, Alabama · Recruiting

  • Providence Alaska Medical Center

    Anchorage, Alaska · Recruiting

  • Banner Children's at Desert

    Mesa, Arizona · Recruiting

  • Phoenix Childrens Hospital

    Phoenix, Arizona · Recruiting

  • Banner University Medical Center - Tucson

    Tucson, Arizona · Recruiting

  • Arkansas Children's Hospital

    Little Rock, Arkansas · Recruiting

  • Kaiser Permanente Downey Medical Center

    Downey, California · Recruiting

  • City of Hope Comprehensive Cancer Center

    Duarte, California · Recruiting

  • Loma Linda University Medical Center

    Loma Linda, California · Recruiting

  • Miller Children's and Women's Hospital Long Beach

    Long Beach, California · Recruiting

  • Children's Hospital Los Angeles

    Los Angeles, California · Recruiting

  • Cedars-Sinai Medical Center

    Los Angeles, California · Recruiting

  • Mattel Children's Hospital UCLA

    Los Angeles, California · Suspended

  • Valley Children's Hospital

    Madera, California · Recruiting

  • UCSF Benioff Children's Hospital Oakland

    Oakland, California · Recruiting

  • Kaiser Permanente-Oakland

    Oakland, California · Recruiting

  • Children's Hospital of Orange County

    Orange, California · Recruiting

  • Lucile Packard Children's Hospital Stanford University

    Palo Alto, California · Recruiting

  • Sutter Medical Center Sacramento

    Sacramento, California · Recruiting

  • University of California Davis Comprehensive Cancer Center

    Sacramento, California · Recruiting

  • Rady Children's Hospital - San Diego

    San Diego, California · Recruiting

  • Naval Medical Center -San Diego

    San Diego, California · Recruiting

  • UCSF Medical Center-Mission Bay

    San Francisco, California · Recruiting

  • Santa Barbara Cottage Hospital

    Santa Barbara, California · Recruiting

  • Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

    Torrance, California · Active not recruiting

  • Children's Hospital Colorado

    Aurora, Colorado · Recruiting

  • Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center

    Denver, Colorado · Recruiting

  • Connecticut Children's Medical Center

    Hartford, Connecticut · Recruiting

  • Yale University

    New Haven, Connecticut · Recruiting

  • Alfred I duPont Hospital for Children

    Wilmington, Delaware · Recruiting

  • MedStar Georgetown University Hospital

    Washington D.C., District of Columbia · Suspended

  • Children's National Medical Center

    Washington D.C., District of Columbia · Recruiting

  • Broward Health Medical Center

    Fort Lauderdale, Florida · Recruiting

  • Golisano Children's Hospital of Southwest Florida

    Fort Myers, Florida · Recruiting

  • UF Health Cancer Institute - Gainesville

    Gainesville, Florida · Recruiting

  • Memorial Regional Hospital/Joe DiMaggio Children's Hospital

    Hollywood, Florida · Recruiting

  • Nemours Children's Clinic-Jacksonville

    Jacksonville, Florida · Recruiting

  • Palms West Radiation Therapy

    Loxahatchee Groves, Florida · Active not recruiting

  • University of Miami Miller School of Medicine-Sylvester Cancer Center

    Miami, Florida · Recruiting

Showing 40 of 231 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.